Abstract
Objective This study investigates the effectiveness of booster doses on the Omicron wave in morocco against COVID-19 severe and critical hospitalizations and deaths;
Participants/methods This study uses nationally representative data on COVID-19 from 15 December 2021 to 31 January 2022. to investigate the effectiveness of the inactivated COVID-19 vaccine BBIBP-CorV (Vero Cells) Sinopharm booster doses on the Omicron wave in morocco by using real-world data established from nationally representative statistics on COVID-19 cases, deaths and vaccinations.
Statistical Analyses Screening method was used to Estimate vaccine effectiveness against COVID-19 severe or critical hospitalization and COVID 19 related deaths. The data were grouped by, age subgroup, sex, week, and geographical area and were analysed by using binary logistic regression with an offset (incorporating expected PPV by third dose and Sinopharm vaccine) for vaccine coverage.
Results The overall sinopharm VE estimate is 89% (95% CI 85 to 92) effective in curbing COVID-19 death, and 81% (95% CI 78 to 84 in curbing COVID-19 severe critical hospitalization. Death related VE estimate was 86% (95% CI 81 to 90) for patients aged 1Z65 years, and 96% (95% CI 90 to 98) for those aged < 65 years, 95% (95% CI 88 to 98) in no risk factor patient was, 91% (95% CI 85 to 94) with 1 risk factor; 90% (95% CI 83 to 95) with 2 risk factors; 72% (95% CI 52 to 84) in patient with 3 risk factors and more. Severe critical hospitalization VE, estimate was 78% (95% CI 74 to 82) for patients aged 1Z65 years, 87% (95% CI 82 to 90) for those aged < 65 years, 86% (95% CI 80 to 90) in no risk factor patient was, 80% (95% CI 73 to 84) with 1 risk factor; 80% (95% CI 70 to 85) with 2 risk factors; 80% (95% CI 68 to 86) in patient with 3 risk factors and more.
Conclusions Sinopharm Boosters are effective in increasing protection against Omicron variant related COVID-19death and severe critical hospitalization. The protection is reduced with older age and higher risk factors. These findings emphasize the importance of targeted vaccination strategies for different demographic groups and underscore the protective benefits of the third booster Sinopharm vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of ethic committee review board for biomedical research at Mohammed V University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author’s mail Jihane Belayachi: j.belayachi{at}um5r.ac.ma, Abdelkader Mhayi: AMhayi{at}sante.gov.ma, Hind Mjidi:hind.majidi222{at}gmail.com, Redouane Abouqal: r.abouqal{at}um5r.ac.ma
Data Availability
The datasets generated for this study are available on request to the corresponding author.
